Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 3 for:    TPIV 200,

Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02593227
Recruitment Status : Completed
First Posted : November 1, 2015
Last Update Posted : July 19, 2021
Sponsor:
Information provided by (Responsible Party):
Marker Therapeutics, Inc.

Tracking Information
First Submitted Date  ICMJE October 27, 2015
First Posted Date  ICMJE November 1, 2015
Last Update Posted Date July 19, 2021
Actual Study Start Date  ICMJE April 2016
Actual Primary Completion Date July 15, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: October 30, 2015)
Immune response [ Time Frame: 3 years ]
Emergence of B and T cell immunity targeting the folate receptor alpha
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: February 25, 2016)
  • Folate receptor alpha expression [ Time Frame: Baseline ]
    To determine FRα expression status of primary tumors
  • Relapse Free Survival [ Time Frame: 3 years ]
    RFS in relation to FR specific immune response
  • Safety and tolerability (treatment emergent adverse events and injection site reactions) [ Time Frame: 3 years ]
    Incidence of treatment emergent adverse events and injection site reactions
Original Secondary Outcome Measures  ICMJE
 (submitted: October 30, 2015)
  • Folate receptor alpha expression [ Time Frame: Baseline ]
    To determine FRα expression status of primary tumors
  • Relapse Free Survival [ Time Frame: 3 years ]
    RFS in relation to FR specific immune response
  • Objective response rate [ Time Frame: 3 years ]
    ORR in the subset of patients with residual disease
  • Safety and tolerability (treatment emergent adverse events and injection site reactions) [ Time Frame: 3 years ]
    Incidence of treatment emergent adverse events and injection site reactions
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
Official Title  ICMJE A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination With Folate Receptor Alpha Peptides With GM-CSF in Patients With Triple Negative Breast Cancer Defined as Primary Tumor That is Her2-neu and Low (< 10%) ER/PR Nuclear Staining
Brief Summary This Phase II trial evaluates the safety and immunogenicity of two doses of the Folate Receptor Alpha (FRα) peptide vaccine mixed with GM-CSF as a vaccine adjuvant, with or without a immune priming with cyclophosphamide, as a consolidation therapy after neoadjuvant or adjuvant treatment of patients with Stage IIb-III triple negative breast cancer (TNBC).
Detailed Description

Triple negative breast cancers (TNBCs) occur in approximately 20-25% of all patients with breast cancer and are associated with a poor prognosis. Patients with TNBCs derive no benefit from targeted therapies. Excluding those patients who demonstrate a pathologic complete response following neoadjuvant chemotherapy, which is a minor fraction (i.e. 15%), overall survival is only 45% at 7 years.

Following standard of care, there are windows of opportunity to further and safely treat patients to prevent recurrence. Stimulating the immune system to produce T cells immunity specific for tumor antigens may significantly delay recurrence and cure patients.

The proposed vaccine is intended to induce T cells to survey for the reemergence of TNBCs and to prevent recurrence in the adjuvant setting. The vaccine strategy is antigen-specific and targets the Folate Receptor Alpha (FRα). FRα is an ideal target because of its limited expression in the healthy tissues and it high expression in 86% of TNBCs. Studies have shown that it is a biologically important marker that is associated with poorer clinical outcome and is retained in metastatic lesions.

The FRα vaccine include a pool of 5 peptides that are immunogenic epitopes and safely generate tissue-surveying CD4 T cell immune responses in patients tested in a recently completed phase I clinical trial.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Breast Cancer
Intervention  ICMJE
  • Biological: Low dose FRα vaccine
    165ug per peptide ID injection
    Other Name: TPIV200
  • Drug: Cyclophosphamide
    IV infusion over 1 hour
    Other Name: Cytoxan
  • Biological: High dose FRα vaccine
    500ug per peptide ID injection
    Other Name: TPIV200
Study Arms  ICMJE
  • Experimental: Low dose FRα vaccine
    FRα peptide vaccine with GM-CSF adjuvant - single ID administration - monthly vaccinations repeated 6 times followed by boosters every 6 months until recurrence
    Intervention: Biological: Low dose FRα vaccine
  • Experimental: High dose FRα vaccine
    FRα peptide vaccine with GM-CSF adjuvant - triple ID administration - monthly vaccinations repeated 6 times followed by boosters every 6 months until recurrence
    Intervention: Biological: High dose FRα vaccine
  • Experimental: Low dose FRα vaccine + cyclophosphamide
    Cyclophosphamide 300 mg/sqm as a 1 hour IV infusion 3 days prior to first vaccination. Followed by FRα peptide vaccine with GM-CSF adjuvant - ID administration - monthly vaccinations repeated 6 times followed by boosters every 6 months until recurrence
    Interventions:
    • Biological: Low dose FRα vaccine
    • Drug: Cyclophosphamide
  • Experimental: High dose FRα vaccine + cyclophosphamide
    Cyclophosphamide 300 mg/sqm as a 1 hour IV infusion 3 days prior to first vaccination. Followed by FRα peptide vaccine with GM-CSF adjuvant - ID administration - monthly vaccinations repeated 6 times followed by boosters every 6 months until recurrence
    Interventions:
    • Drug: Cyclophosphamide
    • Biological: High dose FRα vaccine
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: October 30, 2015)
80
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE July 15, 2021
Actual Primary Completion Date July 15, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Female patient, age 18 years or older;
  2. Completely resected unilateral or bilateral primary carcinoma of the breast
  3. Written informed consent must be obtained and documented according to the local regulatory requirements prior to beginning specific protocol procedures;
  4. Primary tumor was negative for ER, PR (cut-off for positivity is >10% positive tumor cells with nuclear staining) and negative for Her2-neu (0 or 1+ on immunohistochemistry and/or normal gene copy number by in-situ hybridization); Central review is not required.
  5. Completed primary treatment (surgery and radio/chemotherapy in adjuvant and/or neo-adjuvant setting) <360 days prior to first vaccination.
  6. Completed last cycle of chemotherapy or radiation > 60 days prior to first vaccination
  7. Either clinical or pathological Stage I (T1c), II, or III according to AJCC 7th edition

    • Note that patients with (i) non-invasive breast cancer (DCIS) alone, (ii) incidental (microscopic) nodal cancer without a primary tumor (pN1mi), or (iii) metastatic disease are excluded.
    • Resected tumor: No evidence of gross tumor at the surgical resection margin noted in the final surgery report. No evidence of gross residual adenopathy
  8. Karnofsky index >= 70%;
  9. Life expectancy of at least 5 years, disregarding the diagnosis of cancer;
  10. Adequate Blood, renal and hepatic function, as determined within 28 days from registration:

    • ANC ≥ 1,500 / mm3
    • Platelet ≥ 100,000 / uL
    • Hgb > 9 g/dL
    • Creatinine ≤ 1.5 x ULN or 24-hour urine < Grade 2
    • Urinalysis with < 2+ proteinuria
    • Serum albumin ≥ 3 g/dL
    • SGOT (AST) ≤ 3 x ULN
  11. Anti-nuclear antibody (ANA) negative or low-positive institutional range, as determined within 28 days from registration. Intermediate values (usually defined by a titer of ≤1:80, or as indicated by institutional range) are acceptable if there are, in the opinion of the Investigator, no early signs of an autoimmune disease.
  12. Primary tumor is available for shipment to central laboratory for analysis of FRα expression by IHC.
  13. Patients must be, in the opinion of the Investigator, available and compliant for treatment and follow-up.

Exclusion Criteria:

  1. Clinical evidence of distant metastases per practice guidelines for breast cancer;
  2. Inflammatory breast cancer or tumor with deep adherence or cutaneous invasion;
  3. Known hypersensitivity reaction to the GM-CSF adjuvant; Any known contra-indication to GM-CSF or Cyclophosphamide treatment;
  4. Pregnant or lactating patients. Patients of childbearing potential must have a negative pregnancy test (urine or serum) within 7 days prior to registration and must implement adequate contraceptive measures during study treatment;
  5. Active autoimmune disease requiring therapy within the past 2 years (Note: patients with vitiligo, Grave's disease or psoriasis not requiring systemic treatment within the past 2 years are not excluded);
  6. Other uncontrolled illness or medical condition, such as active infection, symptomatic heart failure (New York Heart Association class III or IV; moderate to severe objective evidence of cardiovascular disease), unstable angina pectoris, myocardial infarction or stroke within last 6 months, psychiatric illness that may limit compliance with study requirement or interfere with the understanding and giving of informed consent;
  7. Prior active secondary malignancy < 5 years prior to consent (except non-melanomatous skin cancer or carcinoma in situ of the uterine cervix) or currently receiving other specific treatment for this cancer (including monoclonal antibody or pathway inhibitor);
  8. Completed treatment with systemic corticosteroid or immune-modulators < 30 days prior to registration;
  9. Planned treatment with other experimental drugs or any other non-hormonal anti-cancer therapy;
  10. Immunocompromised patients, including patients with known HIV infection;
  11. Symptomatic thyroid disease, unless negative for thyroid antibodies (TSH receptor, TPO, thyroglobulin).
Sex/Gender  ICMJE
Sexes Eligible for Study: Female
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02593227
Other Study ID Numbers  ICMJE FRV-002
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Marker Therapeutics, Inc.
Study Sponsor  ICMJE Marker Therapeutics, Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Richard Kenney, MD Marker Therapeutics, Inc.
PRS Account Marker Therapeutics, Inc.
Verification Date July 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP